Efficacy of Bloodletting Therapy in Patients with Chronic Idiopathic Urticaria: A Randomized Control Trial

Table 8

Means of SCL90 and treatment comparisons for all time periods.

Time	Group A		Group B		Group C		Pairwise comparisonA
	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	A-B (95%CI)	A-C (95%CI)	B-C (95%CI)
							value	value	value
Baseline	58	128.21	58	120.86	58	121.09
		(4.07)		(4.00)		(3.93)
Week 1	57	116.90	57	115.83	56	117.98	−4.50	−6.10	−1.61
		(25.38)		(29.82)		(28.17)	(−8.56, −0.43)	(−10.18, −2.03)	(−5.67, −2.45)
							0.030	0.004	0.435
Week 2	57	113.60	52	114.25	49	115.16	−4.85	−7.28	−2.43
		(24.19)		(30.39)		(26.31)	(−9.55, −0.14)	(−12.07, −2.48)	(−7.31, 2.44)
							0.044	0.003	0.326
Week 3	53	110.68	50	110.64	45	115.89	−5.56	−10.69	−5.14
		(22.92)		(26.54)		(28.41)	(−10.78, −0.33)	(−16.06, −5.33)	(−10.55, 0.274)
							0.037	<0.001	0.063
Week 4	51	109.61	45	1110.07	44	116.02	−5.37	−11.96	−6.60
		(28.00)		(26.37)		(28.41)	(−10.93, 0.194)	(−17.56, −6.37)	(−12.33, −0.86)
							0.058	<0.001	0.025
Week 5	51	109.20	45	111.33	44	116.25	−7.31	−12.58	−5.26
		(22.51)		(27.93)		(27.34)	(−12.71, −1.922)	(−18.00, −7.15)	(−10.83, 0.30)
							0.008	<0.001	0.063
Week 8	51	109.00	45	111.82	44	115.91	−8.29	−12.61	−4.31
		(222.51)		(32.36)		(32.64)	(−15.52, −1.47)	(−19.48, −5.74)	(−11.36, 2.73)
							0.018	<0.001	0.228

Based on estimated marginal means.